Post-ASH 2025 Lymphoma Highlights

Featuring presentations & discussions on selected lymphoma abstracts from the 67^th ASH Annual Meeting and Exposition

Wednesday 11 February | 10:00 – 12:00 CST/ 16:00 – 18:00 GMT/ 17:00 – 19:00 CET

Chair: Jason Westin | Moderators: Gloria Iacoboni & Laurie Sehn

Register Now

Preliminary Agenda:

Welcome and introductions 

Session 1: Recent progress with chemotherapy treatment and outcomes

Longitudinal circulating tumor DNA dynamics during & after first-line therapy in a national cohort of large B-cell lymphomas (ABSTRACT ID abs25-2126; ABSTRACT ID 474) | Speaker: Steven Wang

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma (ABSTRACT ID abs25-12999; ABSTRACT ID 61) | Speaker: TBC

Interim PET-adapted de-escalation chemotherapy regimen for advanced stage classical Hodgkin lymphoma using vedotin, pembrolizumab, doxorubicin, and dacarbazine: Phase 2 study (ABSTRACT ID abs25-15096; ABSTRACT ID 153) | Speaker: TBC

Panel Discussion

Session 2: Advances with CAR T-cell therapies 

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort (ABSTRACT ID abs25-11098; ABSTRACT ID 662) | Speaker: TBC

A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363 (ABSTRACT ID abs25-234; ABSTRACT ID 265) | Speaker: Saurabh Dahiya 

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results (ABSTRACT ID abs25-8917; ABSTRACT ID 670) | Speaker: TBC

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study (ABSTRACT ID abs25-738; ABSTRACT ID 669) | Speaker: TBC

Rondecabtagene autoleucel, an autologous, dual-targeting CD19/CD20 CAR T-cell candidate manufactured from CD62L+ enriched T cells, achieves durable responses in patients with large B-cell lymphoma (ABSTRACT ID abs25-8476; ABSTRACT ID 668) | Speaker: TBC

Panel Discussion

Session 3: Latest with bispecifics 

Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study (ABSTRACT ID abs25-4494; ABSTRACT ID 228) | Speaker: TBC

Combined mosunetuzumab and zanubrutinib for the treatment of patients with newly diagnosed high-burden follicular lymphoma: First results of the multicenter phase 2 mithic-FL2 trial (ABSTRACT ID abs25-4355; ABSTRACT ID 463) | Speaker: Lorenzo Falchi

Odronextamab plus chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): First Results from part 1 of the Phase 3 Olympia-3 study (ABSTRACT ID abs25-8890; ABSTRACT ID 65) | Speaker: TBC

Primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma (ABSTRACT ID abs25-244; ABSTRACT ID 466) | Speaker: Lorenzo Falchi

Panel Discussion

Session 4: Developments with additional immunotherapies and targeted therapies 

Initial results of a CRUK phase I/II, first in human trial of the CAR T-cell engager protein aleta-001 in patients who have received anti-CD19 CAR T-cell therapy for the treatment of B-cell malignancies (ABSTRACT ID abs25-2651; ABSTRACT ID 925) | Speaker: Sridhar Chaganti

Primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma (ABSTRACT ID abs25-10609; ABSTRACT ID 477) | Speaker: TBC

Sonrotoclax (BGB-11417) monotherapy in patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) previously treated with a bruton tyrosine kinase (BTK) inhibitor: Early results from A phase 1/2 study (ABSTRACT ID abs25-7671; ABSTRACT ID 663) | Speaker: Michael Wang

Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study (ABSTRACT ID abs25-4181; ABSTRACT ID 5359) | Speaker: TBC

Panel Discussion

Session 5: Treatment advances in rare lymphomas 

Results of the primary end-point of the LOC-R01: A randomized phase II study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL) (ABSTRACT ID abs25-1993; ABSTRACT ID 58) | Speaker: Carole Soussain

Interim analysis of safety and efficacy in a Phase 2 study of MB-105, a CD5.CAR T therapy for patients with relapsed/refractory T cell lymphoma (ABSTRACT ID abs25-11504; ABSTRACT ID 775) | Speaker: TBC

Panel Discussion

Conclusions and meeting close